146 related articles for article (PubMed ID: 15078988)
1. The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer.
Rojanala S; Han H; Muñoz RM; Browne W; Nagle R; Von Hoff DD; Bearss DJ
Mol Cancer Ther; 2004 Apr; 3(4):451-7. PubMed ID: 15078988
[TBL] [Abstract][Full Text] [Related]
2. Comparing Aurora A and Aurora B as molecular targets for growth inhibition of pancreatic cancer cells.
Warner SL; Munoz RM; Stafford P; Koller E; Hurley LH; Von Hoff DD; Han H
Mol Cancer Ther; 2006 Oct; 5(10):2450-8. PubMed ID: 17041088
[TBL] [Abstract][Full Text] [Related]
3. Aurora-A transcriptional silencing and vincristine treatment show a synergistic effect in human tumor cells.
Lentini L; Amato A; Schillaci T; Insalaco L; Di Leonardo A
Oncol Res; 2008; 17(3):115-25. PubMed ID: 18669163
[TBL] [Abstract][Full Text] [Related]
4. Kinome-wide siRNA screening identifies molecular targets mediating the sensitivity of pancreatic cancer cells to Aurora kinase inhibitors.
Xie L; Kassner M; Munoz RM; Que QQ; Kiefer J; Zhao Y; Mousses S; Yin HH; Von Hoff DD; Han H
Biochem Pharmacol; 2012 Feb; 83(4):452-61. PubMed ID: 22100984
[TBL] [Abstract][Full Text] [Related]
5. The Aurora kinases: role in cell transformation and tumorigenesis.
Katayama H; Brinkley WR; Sen S
Cancer Metastasis Rev; 2003 Dec; 22(4):451-64. PubMed ID: 12884918
[TBL] [Abstract][Full Text] [Related]
6. Targeting Aurora-2 kinase in cancer.
Warner SL; Bearss DJ; Han H; Von Hoff DD
Mol Cancer Ther; 2003 Jun; 2(6):589-95. PubMed ID: 12813139
[TBL] [Abstract][Full Text] [Related]
7. Akt inhibitor a-443654 interferes with mitotic progression by regulating aurora a kinase expression.
Liu X; Shi Y; Woods KW; Hessler P; Kroeger P; Wilsbacher J; Wang J; Wang JY; Li C; Li Q; Rosenberg SH; Giranda VL; Luo Y
Neoplasia; 2008 Aug; 10(8):828-37. PubMed ID: 18670641
[TBL] [Abstract][Full Text] [Related]
8. Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer.
Gray PJ; Bearss DJ; Han H; Nagle R; Tsao MS; Dean N; Von Hoff DD
Mol Cancer Ther; 2004 May; 3(5):641-6. PubMed ID: 15141022
[TBL] [Abstract][Full Text] [Related]
9. Golgi partitioning controls mitotic entry through Aurora-A kinase.
Persico A; Cervigni RI; Barretta ML; Corda D; Colanzi A
Mol Biol Cell; 2010 Nov; 21(21):3708-21. PubMed ID: 20844084
[TBL] [Abstract][Full Text] [Related]
10. Gefitinib inhibits the proliferation of pancreatic cancer cells via cell cycle arrest.
Zhou X; Zheng M; Chen F; Zhu Y; Yong W; Lin H; Sun Y; Han X
Anat Rec (Hoboken); 2009 Aug; 292(8):1122-7. PubMed ID: 19645012
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of cell proliferation by a resveratrol analog in human pancreatic and breast cancer cells.
Hong YB; Kang HJ; Kim HJ; Rosen EM; Dakshanamurthy S; Rondanin R; Baruchello R; Grisolia G; Daniele S; Bae I
Exp Mol Med; 2009 Mar; 41(3):151-60. PubMed ID: 19293634
[TBL] [Abstract][Full Text] [Related]
12. Aurora kinases: new targets for cancer therapy.
Carvajal RD; Tse A; Schwartz GK
Clin Cancer Res; 2006 Dec; 12(23):6869-75. PubMed ID: 17145803
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of Rho GTPases with Clostridium difficile toxin B impairs centrosomal activation of Aurora-A in G2/M transition of HeLa cells.
Ando Y; Yasuda S; Oceguera-Yanez F; Narumiya S
Mol Biol Cell; 2007 Oct; 18(10):3752-63. PubMed ID: 17634283
[TBL] [Abstract][Full Text] [Related]
14. Growth suppression and mitotic defect induced by JNJ-7706621, an inhibitor of cyclin-dependent kinases and aurora kinases.
Matsuhashi A; Ohno T; Kimura M; Hara A; Saio M; Nagano A; Kawai G; Saitou M; Takigami I; Yamada K; Okano Y; Shimizu K
Curr Cancer Drug Targets; 2012 Jul; 12(6):625-39. PubMed ID: 22463590
[TBL] [Abstract][Full Text] [Related]
15. ZM447439, a novel promising aurora kinase inhibitor, provokes antiproliferative and proapoptotic effects alone and in combination with bio- and chemotherapeutic agents in gastroenteropancreatic neuroendocrine tumor cell lines.
Georgieva I; Koychev D; Wang Y; Holstein J; Hopfenmüller W; Zeitz M; Grabowski P
Neuroendocrinology; 2010; 91(2):121-30. PubMed ID: 19923785
[TBL] [Abstract][Full Text] [Related]
16. On the role of aurora-A in centrosome function.
Dutertre S; Descamps S; Prigent C
Oncogene; 2002 Sep; 21(40):6175-83. PubMed ID: 12214247
[TBL] [Abstract][Full Text] [Related]
17. Amplification and overexpression of Aurora-A in esophageal squamous cell carcinoma.
Yang SB; Zhou XB; Zhu HX; Quan LP; Bai JF; He J; Gao YN; Cheng SJ; Xu NZ
Oncol Rep; 2007 May; 17(5):1083-8. PubMed ID: 17390048
[TBL] [Abstract][Full Text] [Related]
18. [Aurora kinases and cancer].
Kimura M; Okano Y
Gan To Kagaku Ryoho; 2005 Jan; 32(1):1-5. PubMed ID: 15675572
[TBL] [Abstract][Full Text] [Related]
19. Dynamic association of a tumor amplified kinase, Aurora-A, with the centrosome and mitotic spindle.
Stenoien DL; Sen S; Mancini MA; Brinkley BR
Cell Motil Cytoskeleton; 2003 Jun; 55(2):134-46. PubMed ID: 12740874
[TBL] [Abstract][Full Text] [Related]
20. Expression of ROCK-1 in human pancreatic cancer: its down-regulation by morpholino oligo antisense can reduce the migration of pancreatic cancer cells in vitro.
Kaneko K; Satoh K; Masamune A; Satoh A; Shimosegawa T
Pancreas; 2002 Apr; 24(3):251-7. PubMed ID: 11893932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
